Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: JAMA Otolaryngol Head Neck Surg. 2015 Dec 1;141(12):1133–1139. doi: 10.1001/jamaoto.2015.2381

Figure 5. Model Summarizing the Antitumor Effects of Ficlatuzumab on Paracrine Stimulation of HNSCC by TAF-Secreted HGF.

Figure 5

Hepatocyte growth factor (HGF) binds to the tyrosine kinase receptor. Activation of downstream signal molecules facilitates head and neck squamous carcinoma (HNSCC) cell proliferation, migration, and invasion. Ficlatuzumab, a monoclonal antibody binds HGF, downregulating c-Met and downstream targets, inhibiting HNSCC proliferation, migration and invasion. TAF indicates tumor-associated fibroblast.